The marijuana plant (cannabis sativa) contains cannabinoids which can be helpful in the management of pain for many types of illnesses, such as; arthritis, diabetes, multiple sclerosis, epilepsy and nausea to name a few.
Cannabidiol (Also known as CBD, a derivative of the sativa plant) is now playing a role in the treatment of mental illnesses such as depression, anxiety, extreme stress and schizophrenia. Mental illness can severely affect an individuals life, including their relationships, sleeping patterns, careers and more. Including CBD into the diet may just be able to help alleviate a patients distress with a mental illness.
In the past few years, a large number of studies applying THC, the prime active factor derivative of the cannabis plant, or cannabinoid synthetic derivatives have massively contributed to developing the understanding of the pharmacology and neurobiological actions made by cannabinoid receptor triggering. Cannabis has been used to provide solace with some of the signs related to central nervous system syndromes. These days, there is anecdotal proof for the appliance of marijuana in many people dealing with multiple sclerosis or chronic pain.
Following past results on the use of cannabis for medicinal reasons, recent studies have pointed at the potential of cannabinoids to heal a wide range of clinical syndromes. Some of these syndromes that are being looked at are pain, motor dysfunctions, or psychiatric illness. On the other hand, marijuana addiction has been associated with several psychiatric syndromes such as:
Considering that marijuana or cannabinoid pharmaceutical agents may no longer be exclusively recreational substances but may also hold potential therapeutic applications, it has become of great intrigue to review the neurobiological and behavioural impacts of their appliance. This study tries to build a bridge between knowing the basic neurobiology of the endocannabinoid system to novel chances for therapeutic interference and its impacts on the central nervous system.
The considerable development in the pharmacological and physiological actions of THC or cannabinoid synthetic derivatives (agonists and antagonists) has led to the discovery of an endogenous cannabinoid system in the central nervous system. The neuromodulatory job of this new neuronal system massively indicates that direct or indirect modulations of this cannabinoid system using receptor agonists, antagonists or specific inducers of reuptake systems of the endogenous cannabinoids might be possibly applicable in the healing of a wide range of neuropsychiatric syndromes.